Related Experiment Video
Updated: Aug 16, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy
Sinan A Simsir1, Shu S Lin, Laura J Blue
1Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Abstract:
Doxorubicin-induced cardiomyopathy is not uncommon and may progress to end-stage heart failure. Treatment of this condition with heart transplantation, however, requires that the primary malignancy be deemed "cured." We present the case of a 55- year-old woman who had doxorubicin-induced cardiomyopathy and non-Hodgkin's lymphoma. The active status of her lymphoma precluded heart transplantation. She had end-stage heart failure and underwent the insertion of a left ventricular assist device as a destination therapy.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: Inotropic Agents